MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

MKK7-COV-9

CAS No. : 2283355-59-7

MCE 站：MKK7-COV-9

产品活性：MKK7-COV-9 是一种有效的、选择性的 MKK7 共价抑制剂，靶向 MKK7 的一种特异性蛋白-蛋白相互作用。MKK7-COV-9 阻断了原代 B 细胞应对 LPS 的激活的 EC₅₀ 值为 4.98 μM.

研究领域：MAPK/ERK Pathway

作用靶点：p38 MAPK

In Vitro: Due to poor permeability, the?piperidine?analogs MKK7-COV-10 and MKK7-COV-11 proves to be inactive in ICW in 3T3 cells, as well as the carboxylic acid MKK7-COV-8. In contrast, as an?amide?counterpart , MKK7-COV-9, retains activity (EC₅₀=4.06?μM) and furthermore now provides a new vector for further?derivatization.
MKK7-COV-9 (10?μM; 48 hours) shows limited cytotoxic effect only at the highest tested concentration. Only one cell line, HCT116, displayed?half-maximal lethal dose (LD₅₀)<10?μM for these two compounds.
MKK7-COV-9?(10?μM; 2?hr pre-incubation) is able to inhibit 60% of the CD86⁺ response in response to LPS stimulation,?in primary mouse B cells?, except the negative control MKK7-NEG-1.
JNK is known to mediate activation of B cells in response to?lipopolysaccharide (LPS; HY-D1056) through the?TLR4?signaling pathway.
MKK7-COV-9 (0-10 μM; 2?hr pre-incubation) is able to mediate activation of B cells in response to?LPS through the?TLR4?signaling pathway, it shows a dose-response curves for inhibition of LPS induced activation and exhibits an EC₅₀ value of 4.98 μM.(EC₅₀=4.98 μM for MKK7-COV-12; EC₅₀>10 μM for MKK7-COV-7; EC₅₀=2.23 μM for JNK-IN-8).

相关产品：SB 203580  |  SB 202190  |  Doramapimod  |  Losmapimod  |  BI-3406  |  Dehydrocorydaline chloride  |  SB 239063  |  Ralimetinib dimesylate  |  TAK-715  |  Hesperetin  |  PD 169316  |  Pexmetinib  |  VX-702  |  Dilmapimod  |  Talmapimod  |  PH-797804  |  Acumapimod  |  Neflamapimod  |  Pamapimod  |  R1487 Hydrochloride  |  TA-01  |  SB 242235  |  SKF-86002  |  Bakuchiol  |  ITX5061  |  Licochalcone E  |  p38α inhibitor 1  |  PF-3644022  |  Skatole

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。